A multimeric immunogen for the induction of immune memory to beta-amyloid

Francesca Mantile, Carla Basile, Valeria Cicatiello, Diana De Falco, Antonella Caivano, Piergiuseppe De Berardinis, Antonella Prisco

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The development of active immunotherapy for Alzheimer's disease (AD) requires the identification of immunogens that can ensure a high titer antibody response toward beta-amyloid, whereas minimizing the risks of a cell-mediated adverse reaction. We describe here two novel anti-beta-amyloid vaccines that consist of virus like particles formed by a domain of the bacterial protein E2 that is able to self-assemble into a 60-mer peptide. Peptides 1-11 and 2-6 of beta-amyloid were displayed as N terminal fusions on the surface of the E2 particles. E2-based vaccines induced a fast-rising, robust and persistent antibody response to beta-amyloid in all vaccinated mice. The immune memory induced by a single administration of vaccine (1-11) E2 can be rapidly mobilized by a single booster injection, leading to a very high serum concentration of anti-beta-amyloid antibodies (above 1 mg ml 1). E2 vaccination polarizes the immune response toward the production of the anti-inflammatory cytokine interleukin-4 and does not induce a T cell response to beta-amyloid. Thus, E2-based vaccines are promising candidates for the development of immunotherapy protocols for AD.

Original languageEnglish
Pages (from-to)604-609
Number of pages6
JournalImmunology and Cell Biology
Volume89
Issue number5
DOIs
Publication statusPublished - Jul 2011

Fingerprint

Amyloid
Vaccines
Antibody Formation
Alzheimer Disease
Virus-Like Particle Vaccines
Active Immunotherapy
Peptides
Bacterial Proteins
Interleukin-4
Immunotherapy
Vaccination
Anti-Inflammatory Agents
Cytokines
T-Lymphocytes
Injections
Antibodies
Serum

Keywords

  • Alzheimer's disease
  • antibody
  • beta-amyloid
  • immunotherapy

ASJC Scopus subject areas

  • Immunology
  • Cell Biology

Cite this

Mantile, F., Basile, C., Cicatiello, V., De Falco, D., Caivano, A., De Berardinis, P., & Prisco, A. (2011). A multimeric immunogen for the induction of immune memory to beta-amyloid. Immunology and Cell Biology, 89(5), 604-609. https://doi.org/10.1038/icb.2010.134

A multimeric immunogen for the induction of immune memory to beta-amyloid. / Mantile, Francesca; Basile, Carla; Cicatiello, Valeria; De Falco, Diana; Caivano, Antonella; De Berardinis, Piergiuseppe; Prisco, Antonella.

In: Immunology and Cell Biology, Vol. 89, No. 5, 07.2011, p. 604-609.

Research output: Contribution to journalArticle

Mantile, F, Basile, C, Cicatiello, V, De Falco, D, Caivano, A, De Berardinis, P & Prisco, A 2011, 'A multimeric immunogen for the induction of immune memory to beta-amyloid', Immunology and Cell Biology, vol. 89, no. 5, pp. 604-609. https://doi.org/10.1038/icb.2010.134
Mantile F, Basile C, Cicatiello V, De Falco D, Caivano A, De Berardinis P et al. A multimeric immunogen for the induction of immune memory to beta-amyloid. Immunology and Cell Biology. 2011 Jul;89(5):604-609. https://doi.org/10.1038/icb.2010.134
Mantile, Francesca ; Basile, Carla ; Cicatiello, Valeria ; De Falco, Diana ; Caivano, Antonella ; De Berardinis, Piergiuseppe ; Prisco, Antonella. / A multimeric immunogen for the induction of immune memory to beta-amyloid. In: Immunology and Cell Biology. 2011 ; Vol. 89, No. 5. pp. 604-609.
@article{0e57064b56904062b8efeb74e2041e20,
title = "A multimeric immunogen for the induction of immune memory to beta-amyloid",
abstract = "The development of active immunotherapy for Alzheimer's disease (AD) requires the identification of immunogens that can ensure a high titer antibody response toward beta-amyloid, whereas minimizing the risks of a cell-mediated adverse reaction. We describe here two novel anti-beta-amyloid vaccines that consist of virus like particles formed by a domain of the bacterial protein E2 that is able to self-assemble into a 60-mer peptide. Peptides 1-11 and 2-6 of beta-amyloid were displayed as N terminal fusions on the surface of the E2 particles. E2-based vaccines induced a fast-rising, robust and persistent antibody response to beta-amyloid in all vaccinated mice. The immune memory induced by a single administration of vaccine (1-11) E2 can be rapidly mobilized by a single booster injection, leading to a very high serum concentration of anti-beta-amyloid antibodies (above 1 mg ml 1). E2 vaccination polarizes the immune response toward the production of the anti-inflammatory cytokine interleukin-4 and does not induce a T cell response to beta-amyloid. Thus, E2-based vaccines are promising candidates for the development of immunotherapy protocols for AD.",
keywords = "Alzheimer's disease, antibody, beta-amyloid, immunotherapy",
author = "Francesca Mantile and Carla Basile and Valeria Cicatiello and {De Falco}, Diana and Antonella Caivano and {De Berardinis}, Piergiuseppe and Antonella Prisco",
year = "2011",
month = "7",
doi = "10.1038/icb.2010.134",
language = "English",
volume = "89",
pages = "604--609",
journal = "Immunology and Cell Biology",
issn = "0818-9641",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - A multimeric immunogen for the induction of immune memory to beta-amyloid

AU - Mantile, Francesca

AU - Basile, Carla

AU - Cicatiello, Valeria

AU - De Falco, Diana

AU - Caivano, Antonella

AU - De Berardinis, Piergiuseppe

AU - Prisco, Antonella

PY - 2011/7

Y1 - 2011/7

N2 - The development of active immunotherapy for Alzheimer's disease (AD) requires the identification of immunogens that can ensure a high titer antibody response toward beta-amyloid, whereas minimizing the risks of a cell-mediated adverse reaction. We describe here two novel anti-beta-amyloid vaccines that consist of virus like particles formed by a domain of the bacterial protein E2 that is able to self-assemble into a 60-mer peptide. Peptides 1-11 and 2-6 of beta-amyloid were displayed as N terminal fusions on the surface of the E2 particles. E2-based vaccines induced a fast-rising, robust and persistent antibody response to beta-amyloid in all vaccinated mice. The immune memory induced by a single administration of vaccine (1-11) E2 can be rapidly mobilized by a single booster injection, leading to a very high serum concentration of anti-beta-amyloid antibodies (above 1 mg ml 1). E2 vaccination polarizes the immune response toward the production of the anti-inflammatory cytokine interleukin-4 and does not induce a T cell response to beta-amyloid. Thus, E2-based vaccines are promising candidates for the development of immunotherapy protocols for AD.

AB - The development of active immunotherapy for Alzheimer's disease (AD) requires the identification of immunogens that can ensure a high titer antibody response toward beta-amyloid, whereas minimizing the risks of a cell-mediated adverse reaction. We describe here two novel anti-beta-amyloid vaccines that consist of virus like particles formed by a domain of the bacterial protein E2 that is able to self-assemble into a 60-mer peptide. Peptides 1-11 and 2-6 of beta-amyloid were displayed as N terminal fusions on the surface of the E2 particles. E2-based vaccines induced a fast-rising, robust and persistent antibody response to beta-amyloid in all vaccinated mice. The immune memory induced by a single administration of vaccine (1-11) E2 can be rapidly mobilized by a single booster injection, leading to a very high serum concentration of anti-beta-amyloid antibodies (above 1 mg ml 1). E2 vaccination polarizes the immune response toward the production of the anti-inflammatory cytokine interleukin-4 and does not induce a T cell response to beta-amyloid. Thus, E2-based vaccines are promising candidates for the development of immunotherapy protocols for AD.

KW - Alzheimer's disease

KW - antibody

KW - beta-amyloid

KW - immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=79959953238&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959953238&partnerID=8YFLogxK

U2 - 10.1038/icb.2010.134

DO - 10.1038/icb.2010.134

M3 - Article

C2 - 21102534

AN - SCOPUS:79959953238

VL - 89

SP - 604

EP - 609

JO - Immunology and Cell Biology

JF - Immunology and Cell Biology

SN - 0818-9641

IS - 5

ER -